<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01961271</url>
  </required_header>
  <id_info>
    <org_study_id>BUP12-AP-401</org_study_id>
    <nct_id>NCT01961271</nct_id>
  </id_info>
  <brief_title>Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain</brief_title>
  <official_title>Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mundipharma Korea Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mundipharma (Hong Kong) Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mundipharma Distribution GmBH (Philippine Branch)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mundipharma Pte Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of the buprenorphine transdermal patch
      (Norspan® or Sovenor® transdermal patch) in patients with chronic non-malignant pain of
      moderate to severe intensity due to osteoarthritis, rheumatoid arthritis, lower back pain and
      joint/muscle pain, who are not adequately responding to non-opioid painkillers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Baseline assessment (Visit 1) includes medical history, physical examination, vital signs.

      At Visit 2 [7 days ( ± 3 days) after Visit 1] and subsequent optional titration visits up to
      (Visit 1 + 42 days) , patients will be titrated up to an effective and tolerated dose of
      Norspan® or Sovenor® transdermal patch and continue rescue analgesic, if necessary.

      Titration period is dependent on time to achieving optimal pain control as determined by the
      investigator. The up-titration regime is planned on a weekly basis. Earlier dose titration
      (i.e. minimum 3 days after the patch application) is permitted at the investigator's
      discretion if the pain is uncontrolled. Effective and tolerated dose is assessed by data
      recorded in the case report form and patient diary.

      According to country label, all patients will begin treatment with Norspan® or Sovenor®
      transdermal patch 5mg and will then be up-titrated, if necessary, to a maximum of Norspan® or
      Sovenor® transdermal patch 40mg or according to country label to achieve stable pain control.
      Patients that require oral opioid at any time during the study should be discontinued from
      the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy According to BS-11 Pain Score Reduction</measure>
    <time_frame>Maximum 17 weeks starting from enrolment</time_frame>
    <description>The primary efficacy outcome analysis is the pre- and post-intervention change in BS-11 pain score. The reduction in scores were calculated by subtracting the post-intervention score from the baseline score.
BS-11 is known as &quot;Box scale-11&quot;; it is an 11-point scale measuring pain intensity. It ranges from 0 to 10, whereby 0 represents no pain and 10 represents the worst imaginable pain. Subjects selected a number based on the pain intensity they were feeling at that time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome Determined by Change in Percentage of Subjects Who Met Criteria on EQ5D-3L Quality of Life Questionnaire From Pre- to Post-intervention</measure>
    <time_frame>approximately 17 weeks starting from enrolment</time_frame>
    <description>Pre-intervention: Visit 1 Post-intervention: Visit 6
There are 5 dimensions in the EQ5D-3L questionnaire answered by the subjects, classified into 5 categories here:
Mobility -- change in % of subjects who have no problem in walking around Self-care -- change in % of subjects who have no problem in self-care Usual activities -- change in % of subjects who have no problem with performing their usual activities Pain/ discomfort -- change in % of subjects who do not experience pain or discomfort Anxiety/ depression -- change in % of subjects who do not feel anxious or depressed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse Events (TEAE's) as Measured by Number of Subjects With at Least 1 TEAE</measure>
    <time_frame>From time of enrolment up to 7 days after completion / discontinuation visit (up to 140 days)</time_frame>
    <description>Side effects of the transdermal patch treatment will be analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome as Measured by Number of Subjects Requiring at Least 1 Breakthrough (Rescue) Pain Medication</measure>
    <time_frame>Approximately 17 weeks starting from enrolment</time_frame>
    <description>Daily use of breakthrough pain medication from visits 1-6, assessed from patient diaries.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome on Physicians' and Patients' Treatment Satisfaction Assessed Using Physician's Global Impression of Change Scale and Patient's Global Impression of Change Scale Respectively</measure>
    <time_frame>At visit 6 (anywhere between Day 91 to 119 after enrolment depending on how long titration took)</time_frame>
    <description>The overall assessment of the change in pain intensity from baseline is measured at Visit 6.
Physician's Global Impression of Change scale: Investigator's opinion on a scale of 1 to 7 where 1 is &quot;very much improved&quot; and 7 is &quot;very much worse&quot; Patient's Global Impression of Change scale: Subject's opinion on a scale of 1 to 7 where 1 is &quot;very much improved&quot; and 7 is &quot;very much worse&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Outcome -- Incidence of Early Treatment Discontinuation Due to Lack of Efficacy.</measure>
    <time_frame>From time of enrolment to Visit 6 (ie. up to119 days from enrolment)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Lower Back Pain</condition>
  <condition>Joint Pain</condition>
  <condition>Muscle Pain</condition>
  <arm_group>
    <arm_group_label>Buprenorphine transdermal patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine transdermal patch</intervention_name>
    <description>Please see Arm Description.</description>
    <arm_group_label>Buprenorphine transdermal patch</arm_group_label>
    <other_name>Norspan transdermal patch</other_name>
    <other_name>Sovenor transdermal patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females aged 18-80 years (both inclusive) at the time of recruitment.

          2. Clinical diagnosis of osteoarthritis, rheumatoid arthritis, lower back pain or joint /
             muscle pain.

          3. Having non-malignant pain of moderate or severe intensity requiring an opioid for
             adequate analgesia (according to local label of Norspan® or Sovenor®). This is to be
             determined using BS-11 scores, where the cut-off point is ≥4.

          4. Patients with chronic uncontrolled pain and is assessed to require opioid treatment
             but have not been treated with opioids (including tramadol, morphine etc.) within 4
             weeks or more before study entry.

        Exclusion Criteria:

          1. Pregnant and lactating females.

          2. Patients with chronic condition(s), in addition to osteoarthritis, that require(s)
             frequent analgesic treatment (e.g. frequent headaches, frequent migraine, and gout).

          3. Patients who are awaiting a scheduled operation or other surgical procedure during
             study period or 3 months or less post-operative.

          4. Prior history of being on opioids in the preceding 1 month prior to the study for the
             management of chronic non-malignant pain.

          5. Prior history of buprenorphine transdermal system use.

          6. Patients with history of allergic reactions against paracetamol/ acetaminophen, NSAIDs
             and/or opioids.

          7. Patients with allergies or other contraindications to transdermal systems or patch
             adhesives.

          8. Patients with dermatological disorders who may have problems applying patch or
             rotating patch placement area.

          9. Patients with cancer (except for basal cell carcinoma) or history of cancer who have
             been diagnosed within five years prior to the first study visit (except for treated
             basal cell carcinoma).

         10. Patients with conditions such as brain tumour, brain injury or raised intracranial
             pressure.

         11. Patients with history of psychiatric disorder, uncontrollable epilepsy, untreated
             depression or other psychiatric disorders of a type that would make participation in
             the study an unacceptable risk to the patient.

         12. Patients with any conditions causing poor cognitive function as assessed by the
             participating physician.

         13. Patients with history of alcohol and drug abuse or patients who have demonstrated
             behaviour that suggests a dependency or drug abuse.

         14. Patients currently taking hypnotics or other central nervous system depressants that
             may pose a risk of additional central nervous system depression with study medication.

         15. Patients who are currently being administered monoamine oxidase inhibitors (MAOIs) or
             have taken MAOIs within 2 weeks before screening.

         16. Patients requiring dose titration of adjuvant analgesics i.e. antidepressants (e.g.
             amitriptyline, amoxapine, clomipramine, selective serotonin re-uptake inhibitors
             (SSRIs)) and anticonvulsants (e.g. gabapentin, pregabalin). Patients will be allowed
             to enter the study as long as they are on the stable doses of adjuvant analgesics at
             screening and do not have dose adjustments during the study.

         17. Patients who have received steroid treatment (intra-articular, intramuscular, oral,
             intravenous, epidural or other corticosteroid injections) within 6 weeks prior to
             clinical study or planned steroid treatment during the clinical study period.

         18. Patients who have to use heating facility (examples: heating lamp, electric blanket,
             sauna, warm compresses, heated saline baths, etc.).

         19. Patients who cannot or do not wish to remove hair growing at body surface where the
             patch can be placed.

         20. Patients who are currently on disability claims or in the process of applying for
             disability claims.

         21. Patients at child-bearing age who are planning to conceive a child during the study
             period and are not practicing adequate contraception.

         22. Patients with known severe hepatic impairment as determined by liver function test
             within the past one year.

         23. Patients who are currently in or have participated in other clinical trials within the
             last 30 days prior to study recruitment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pok Oi Hospital</name>
      <address>
        <city>Yuen Long</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Gascoigne Road</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital (Dept of Anaesthesiology)</name>
      <address>
        <city>Pokfulam Road</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital (Dept of Rheumatology)</name>
      <address>
        <city>Pokfulam Road</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-Gu</city>
        <state>Seoul</state>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital (Dept of Neurology)</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital (Dept of Orthopedics)</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seocho-gu</city>
        <state>Seoul</state>
        <zip>137701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>120752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-Gu</city>
        <state>Seoul</state>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makati Medical Center</name>
      <address>
        <city>Makati City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Santo Tomas Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <results_first_submitted>March 29, 2016</results_first_submitted>
  <results_first_submitted_qc>August 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2016</results_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norspan</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>transdermal</keyword>
  <keyword>patch</keyword>
  <keyword>chronic pain</keyword>
  <keyword>non-malignant</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>lower back pain</keyword>
  <keyword>joint pain</keyword>
  <keyword>muscle pain</keyword>
  <keyword>opioid</keyword>
  <keyword>analgesic</keyword>
  <keyword>painkiller</keyword>
  <keyword>Mundipharma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Buprenorphine Transdermal Patch</title>
          <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Buprenorphine Transdermal Patch</title>
          <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy According to BS-11 Pain Score Reduction</title>
        <description>The primary efficacy outcome analysis is the pre- and post-intervention change in BS-11 pain score. The reduction in scores were calculated by subtracting the post-intervention score from the baseline score.
BS-11 is known as &quot;Box scale-11&quot;; it is an 11-point scale measuring pain intensity. It ranges from 0 to 10, whereby 0 represents no pain and 10 represents the worst imaginable pain. Subjects selected a number based on the pain intensity they were feeling at that time.</description>
        <time_frame>Maximum 17 weeks starting from enrolment</time_frame>
        <population>Subjects of the analysis population met the eligibility criteria. It consists of subjects who completed the study and who withdrew for any reason.</population>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Transdermal Patch</title>
            <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy According to BS-11 Pain Score Reduction</title>
          <description>The primary efficacy outcome analysis is the pre- and post-intervention change in BS-11 pain score. The reduction in scores were calculated by subtracting the post-intervention score from the baseline score.
BS-11 is known as &quot;Box scale-11&quot;; it is an 11-point scale measuring pain intensity. It ranges from 0 to 10, whereby 0 represents no pain and 10 represents the worst imaginable pain. Subjects selected a number based on the pain intensity they were feeling at that time.</description>
          <population>Subjects of the analysis population met the eligibility criteria. It consists of subjects who completed the study and who withdrew for any reason.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Outcome Determined by Change in Percentage of Subjects Who Met Criteria on EQ5D-3L Quality of Life Questionnaire From Pre- to Post-intervention</title>
        <description>Pre-intervention: Visit 1 Post-intervention: Visit 6
There are 5 dimensions in the EQ5D-3L questionnaire answered by the subjects, classified into 5 categories here:
Mobility -- change in % of subjects who have no problem in walking around Self-care -- change in % of subjects who have no problem in self-care Usual activities -- change in % of subjects who have no problem with performing their usual activities Pain/ discomfort -- change in % of subjects who do not experience pain or discomfort Anxiety/ depression -- change in % of subjects who do not feel anxious or depressed</description>
        <time_frame>approximately 17 weeks starting from enrolment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Transdermal Patch</title>
            <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Outcome Determined by Change in Percentage of Subjects Who Met Criteria on EQ5D-3L Quality of Life Questionnaire From Pre- to Post-intervention</title>
          <description>Pre-intervention: Visit 1 Post-intervention: Visit 6
There are 5 dimensions in the EQ5D-3L questionnaire answered by the subjects, classified into 5 categories here:
Mobility -- change in % of subjects who have no problem in walking around Self-care -- change in % of subjects who have no problem in self-care Usual activities -- change in % of subjects who have no problem with performing their usual activities Pain/ discomfort -- change in % of subjects who do not experience pain or discomfort Anxiety/ depression -- change in % of subjects who do not feel anxious or depressed</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual Activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/ Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Adverse Events (TEAE's) as Measured by Number of Subjects With at Least 1 TEAE</title>
        <description>Side effects of the transdermal patch treatment will be analysed.</description>
        <time_frame>From time of enrolment up to 7 days after completion / discontinuation visit (up to 140 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Transdermal Patch</title>
            <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Adverse Events (TEAE's) as Measured by Number of Subjects With at Least 1 TEAE</title>
          <description>Side effects of the transdermal patch treatment will be analysed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Outcome as Measured by Number of Subjects Requiring at Least 1 Breakthrough (Rescue) Pain Medication</title>
        <description>Daily use of breakthrough pain medication from visits 1-6, assessed from patient diaries.</description>
        <time_frame>Approximately 17 weeks starting from enrolment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Transdermal Patch</title>
            <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Outcome as Measured by Number of Subjects Requiring at Least 1 Breakthrough (Rescue) Pain Medication</title>
          <description>Daily use of breakthrough pain medication from visits 1-6, assessed from patient diaries.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Outcome on Physicians' and Patients' Treatment Satisfaction Assessed Using Physician's Global Impression of Change Scale and Patient's Global Impression of Change Scale Respectively</title>
        <description>The overall assessment of the change in pain intensity from baseline is measured at Visit 6.
Physician's Global Impression of Change scale: Investigator's opinion on a scale of 1 to 7 where 1 is &quot;very much improved&quot; and 7 is &quot;very much worse&quot; Patient's Global Impression of Change scale: Subject's opinion on a scale of 1 to 7 where 1 is &quot;very much improved&quot; and 7 is &quot;very much worse&quot;</description>
        <time_frame>At visit 6 (anywhere between Day 91 to 119 after enrolment depending on how long titration took)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Transdermal Patch</title>
            <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Outcome on Physicians' and Patients' Treatment Satisfaction Assessed Using Physician's Global Impression of Change Scale and Patient's Global Impression of Change Scale Respectively</title>
          <description>The overall assessment of the change in pain intensity from baseline is measured at Visit 6.
Physician's Global Impression of Change scale: Investigator's opinion on a scale of 1 to 7 where 1 is &quot;very much improved&quot; and 7 is &quot;very much worse&quot; Patient's Global Impression of Change scale: Subject's opinion on a scale of 1 to 7 where 1 is &quot;very much improved&quot; and 7 is &quot;very much worse&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physician Impression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient Impression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Outcome -- Incidence of Early Treatment Discontinuation Due to Lack of Efficacy.</title>
        <time_frame>From time of enrolment to Visit 6 (ie. up to119 days from enrolment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Buprenorphine Transdermal Patch</title>
            <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Outcome -- Incidence of Early Treatment Discontinuation Due to Lack of Efficacy.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The timeframe is up to 140 days. All adverse events will be recorded from the time the ICF is signed until 7 days after the completion/ discontinuation visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Buprenorphine Transdermal Patch</title>
          <description>Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
Buprenorphine transdermal patch: Please see Arm Description.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gingival Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Application Site Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Application Site Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Application Site Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Application Site Warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Feeling Cold</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza-like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to Arthropod Sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Muscle Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Joint Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypoesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary Hesitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Data emerging from the study cannot be released without the permission of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Valerie Anne Leck</name_or_title>
      <organization>Mundipharma Pte Ltd</organization>
      <phone>+65 6511 1165</phone>
      <email>info.rma@mundipharma.com.sg</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

